Crescent Biopharma (NASDAQ:CBIO) Insider Ellie Eunkyung Im Sells 623 Shares

Crescent Biopharma, Inc. (NASDAQ:CBIO) insider Ellie Im sold 623 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $17.90, for a total value of $11,151.70. Following the completion of the transaction, the insider owned 21,446 shares of the company’s stock, valued at approximately $383,883.40. This represents a 2.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ellie Eunkyung Im also recently made the following trade(s):

• On Monday, June 22nd, Ellie Im sold 1,219 shares of Crescent Biopharma stock. The shares were sold at an average price of $17.99, for a total value of $21,929.81.

Crescent Biopharma Price Performance

Shares of CBIO traded up $0.12 during midday trading on Friday, hitting $16.89. 3,123,507 shares of the company traded hands, compared to its average volume of 294,314. Crescent Biopharma, Inc. has a one year low of $8.72 and a one year high of $27.41. The firm has a market cap of $627.36 million, a P/E ratio of -2.51 and a beta of 1.24. The stock has a 50-day moving average of $17.12 and a 200-day moving average of $17.43.

Crescent Biopharma (NASDAQ:CBIO) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($0.74) EPS for the quarter, meeting the consensus estimate of ($0.74). Sell-side analysts forecast that Crescent Biopharma, Inc. will post -2.91 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. HC Wainwright reissued a “neutral” rating on shares of Crescent Biopharma in a research note on Thursday, July 16th. Wedbush reiterated an “outperform” rating and issued a $27.00 price objective on shares of Crescent Biopharma in a report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Crescent Biopharma in a research report on Friday, August 7th. Finally, TD Cowen raised Crescent Biopharma to a “strong-buy” rating in a report on Monday, August 24th. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $29.60.

Institutional Trading of Crescent Biopharma

Several hedge funds have recently added to or reduced their stakes in CBIO. Opaleye Management Inc. boosted its position in Crescent Biopharma by 0.5% during the second quarter. Opaleye Management Inc. now owns 1,319,351 shares of the biopharmaceutical company’s stock valued at $23,748,000 after buying an additional 6,736 shares during the period. Squarepoint Ops LLC purchased a new position in shares of Crescent Biopharma in the second quarter worth about $435,000. Wellington Management Group LLP purchased a new position in shares of Crescent Biopharma in the second quarter worth about $263,000. Stonepine Capital Management LLC bought a new stake in shares of Crescent Biopharma in the 2nd quarter valued at about $720,000. Finally, Bank of America Corp DE bought a new stake in shares of Crescent Biopharma in the 2nd quarter valued at about $465,000. 75.19% of the stock is owned by institutional investors.

Key Stories Impacting Crescent Biopharma

Here are the key news stories impacting Crescent Biopharma this week:

• Neutral Sentiment: CEO Joshua Brumm, COO Jonathan McNeill, CFO Richard Scalzo, and other insiders collectively sold 16,726 shares worth approximately $285,501 between September 16 and September 18. The sales reduced individual holdings by roughly 0.5% to 3.2%, but insiders continued to retain meaningful positions. SEC insider transaction filing
• Neutral Sentiment: All reported transactions were executed under pre-arranged Rule 10b5-1 trading plans and were described as sales to cover tax-withholding obligations tied to vested equity awards. That reduces the likelihood that the transactions represent a change in management’s outlook, although the aggregate selling may still weigh modestly on sentiment. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by senior executives—including the CEO and COO—could be viewed as a near-term supply or sentiment overhang. However, the relatively small percentage reductions and tax-related rationale make this a limited negative signal rather than a clear indication of weakening business prospects. SEC insider transaction filing

About Crescent Biopharma

Crescent Biopharma, Inc (NASDAQ: CBIO) is a biopharmaceutical company focused on discovering and developing innovative therapies for the treatment of serious diseases. The company’s activities center on research, preclinical development and clinical evaluation of investigational drug candidates.

Crescent Biopharma does not appear to have commercially marketed products. Its pipeline consists of experimental therapies intended to address significant unmet medical needs, although detailed information about specific candidates, therapeutic areas and development stages may be limited in publicly available sources.

The company is headquartered in the United States and serves the biopharmaceutical market through its drug-development programs and potential future partnerships.